c6

Overview

C6 (Complement Component 6) encodes a terminal complement protein that is essential for the formation of the membrane attack complex (MAC), the final effector of the complement cascade. Located on chromosome 5p13.1, C6 encodes a 922-amino acid protein that circulates in plasma and binds to the C5b-7 complex to form C5b-6-7, which then inserts into target cell membranes. The subsequent addition of C8 and C9 completes the MAC, creating a transmembrane pore that can lead to cell lysis. This gene is critical for innate immunity, particularly for defense against Neisseria species, while also playing important roles in immune regulation and tissue homeostasis ^{1The membrane attack complex: from bacterial death to human disease2020 · Molecular Immunology · DOI 10.1016/j.molimm.2020.02.015Open reference}.

The complement system is a major component of innate immunity, and its activation leads to three main outcomes: opsonization (tagging pathogens for phagocytosis), inflammation (attracting immune cells to the site of infection), and cell lysis (direct killing of pathogens through the MAC). C6 is essential for the terminal lytic pathway, and its deficiency leads to increased susceptibility to Neisseria infections. Beyond its role in immunity, increasing evidence implicates complement activation in the pathogenesis of various neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, making C6 increasingly relevant to neurodegenerative disease research ^{2Complement activation in neurological disease2019 · Journal of Neurology · DOI 10.1007/s00415-019-09456-1Open reference}.

Molecular Function and Mechanism

Complement Cascade Overview

The complement system can be activated through three pathways:

1. Classical pathway: Triggered by antigen-antibody complexes

2. Lectin pathway: Activated by mannose-binding lectin

3. Alternative pathway: Spontaneous C3 activation

All pathways converge at the level of C3 activation, leading to downstream events including C5 cleavage and MAC formation.

C6 in the Terminal Pathway

C6 plays a critical role in the final steps of complement activation:

MAC Assembly Sequence:

1. C5 → C5a + C5b (proteolytic cleavage)

2. C5b + C6 → C5b-6 (stable complex formation)

3. C5b-6 + C7 → C5b-6-7 (membrane insertion)

4. C5b-6-7 + C8 → C5b-6-7-8 (pore formation begins)

5. C5b-6-7-8 + C9 → C5b-6-7-8-9 (complete MAC)

Structural Features

The C6 protein contains several functional regions:

• N-terminal domain: Contains cysteine-rich repeats (MCP/CD46-like)

• Thrombospondin type I repeats: Protein-protein interaction motifs

• C-terminal domain: Critical for complex formation with C5b-7

• Disulfide bonds: Stabilize protein structure

Biological Functions

The MAC performs several critical functions:

Pathogen Killing:

• Direct lysis of Gram-negative bacteria

• Defense against Neisseria species

• Immune surveillance against infected cells

Immune Regulation:

• Sublytic MAC signaling

• Induction of inflammation

• Clearance of cellular debris

Tissue Homeostasis:

• Removal of dead cells

• Promotion of tissue repair

• Regulation of immune responses

Disease Associations

Complement Deficiency

C6 deficiency is one of the more common complement component deficiencies:

Clinical Features:

• Recurrent Neisseria infections (especially N. meningitidis)

• Increased susceptibility to bacterial infections

• Usually asymptomatic otherwise

• May be identified through laboratory testing

Genetics:

• Autosomal recessive inheritance

• Multiple pathogenic variants identified

• Carrier parents typically asymptomatic

Alzheimer’s Disease

Complement activation is strongly implicated in AD pathogenesis:

Neuropathological Evidence:

• MAC deposition in AD brain tissue

• C5b-9 accumulation in amyloid plaques

• Colocalization with neurofibrillary tangles

• Association with synaptic loss

Mechanisms:

• Synaptic pruning by microglia (involves complement)

• Enhanced neuroinflammation

• Neuronal loss through sublytic MAC signaling

• Amyloid plaque formation

Therapeutic Implications:

• Complement inhibitors in development

• Targeting specific complement pathways

• Anti-C1q therapies in trials

Parkinson’s Disease

Complement involvement in PD includes:

• Microglial activation: Complement proteins as activators

• Dopaminergic neuron vulnerability: MAC-mediated injury

• α-Synuclein aggregation: Complement interactions

• Neuroinflammation: Chronic inflammatory state

Multiple Sclerosis

Complement plays complex roles in MS:

• Demyelination: MAC-mediated oligodendrocyte injury

• Axonal damage: Complement-dependent mechanisms

• Blood-brain barrier disruption: Inflammatory contributions

• Remyelination failure: Inhibitory effects of complement

Amyotrophic Lateral Sclerosis

Complement in ALS:

• Motor neuron injury: MAC deposition

• Microglial activation: Pro-inflammatory effects

• Astrocyte involvement: Complement signaling

• Therapeutic targeting: Complement inhibitors

Other Neurological Conditions

• Huntington’s disease: Complement dysregulation

• Prion diseases: MAC deposition

• Stroke: Complement-mediated injury

• Traumatic brain injury: Complement activation

Expression Pattern

Tissue Distribution

C6 is primarily expressed in:

• Liver: Primary site of synthesis

• Monocytes/macrophages: Local production

• Astrocytes: Brain expression

• Microglia: CNS production

• Various tissues: Lower expression

Brain Expression

• Astrocytes: Primary CNS source

• Microglial cells: Activated state production

• Neurons: Lower expression

• Oligodendrocytes: Variable

Regulation

C6 expression is regulated by:

• Acute phase response: Upregulated during inflammation

• Cytokines: IL-6, IL-1, TNF-α affect expression

• Tissue-specific factors: Different regulatory mechanisms

• Developmental stage: Variable expression

Therapeutic Implications

Complement Inhibitors

Therapeutic strategies targeting complement include:

1. Anti-C5 therapies:

   • Eculizumab (approved for other conditions)

   • Ravulizumab (longer-acting)

2. C1q inhibitors:

   • Monoclonal antibodies

   • Peptide inhibitors

3. Alternative pathway inhibitors:

   • Factor B inhibitors

   • Factor D inhibitors

Neurological Applications

• ALS: Complement inhibition trials

• AD: Anti-complement strategies

• MS: Remyelination approaches

Gene Therapy

• Liver-directed gene therapy: For complement deficiency

• CRISPR corrections: For genetic forms

Interaction Network

C6 interacts with:

• C5b: Precursor complex

• C7: For membrane insertion

• C8: Pore formation

• C9: Polymerization for lysis

• CD46/CD55: Complement regulators

Diagnostic Significance

• Genetic testing: For C6 deficiency

• Complement assays: CH50 measurement

• Biomarker potential: In neurological disease

Cross-Links

• Complement System

• Membrane Attack Complex

• Neuroinflammation

• Alzheimer’s Disease

• Parkinson’s Disease

See Also

• Complement Pathway

• Innate Immunity

• C5 Gene

• C7 Gene

• C8 Gene

• C9 Gene

External Links

• NCBI Gene: C6

• UniProt: P13671

• Ensembl: ENSG00000124357

• OMIM: 119455